$15.58
1.16%
Downside
Day's Volatility :10.31%
Upside
9.26%
50.96%
Downside
52 Weeks Volatility :74.69%
Upside
48.39%
Period | Cullinan Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -0.36% | 1.4% | 0.0% |
6 Months | -43.85% | 3.8% | 0.0% |
1 Year | 67.14% | 15.3% | 0.0% |
3 Years | -30.02% | 11.4% | -27.4% |
Market Capitalization | 926.5M |
Book Value | $11.34 |
Earnings Per Share (EPS) | -3.06 |
Wall Street Target Price | 32.38 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -19.04% |
Return On Equity TTM | -24.94% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 18.9M |
EBITDA | -183.0M |
Diluted Eps TTM | -3.06 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.26 |
EPS Estimate Next Year | -3.3 |
EPS Estimate Current Quarter | -0.73 |
EPS Estimate Next Quarter | -0.73 |
What analysts predicted
Upside of 107.83%
Sell
Neutral
Buy
Cullinan Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Cullinan Therapeutics Inc | 2.74% | -43.85% | 67.14% | -30.02% | -44.9% |
Regeneron Pharmaceuticals, Inc. | -18.01% | -15.81% | -1.7% | 31.13% | 150.21% |
Biontech Se | -12.27% | 17.34% | 4.17% | -56.04% | 478.94% |
Alnylam Pharmaceuticals, Inc. | 2.34% | 76.9% | 60.41% | 45.24% | 198.24% |
Vertex Pharmaceuticals Incorporated | 10.04% | 20.33% | 30.51% | 156.8% | 152.08% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Cullinan Therapeutics Inc | 9.03 | NA | NA | -3.26 | -0.25 | -0.19 | NA | 11.34 |
Regeneron Pharmaceuticals, Inc. | 20.49 | 20.54 | 1.22 | 44.74 | 0.17 | 0.07 | NA | 272.04 |
Biontech Se | 160.8 | NA | 0.04 | -2.99 | -0.03 | -0.02 | NA | 85.17 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -1.87 | -15.01 | -0.03 | NA | 0.25 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 1.27 | 0.19 | -0.03 | 0.12 | NA | 60.66 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Cullinan Therapeutics Inc | Buy | $923.0M | -44.9% | 9.03 | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $91.1B | 150.21% | 20.49 | 33.61% |
Biontech Se | Buy | $26.5B | 478.94% | 160.8 | -18.75% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.8B | 198.24% | NA | -15.86% |
Vertex Pharmaceuticals Incorporated | Buy | $121.6B | 152.08% | 32.84 | -4.51% |
Insights on Cullinan Therapeutics Inc
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 45.8% return, outperforming this stock by 74.6%
MPM Oncology Impact Management LP
Bvf Inc
BlackRock Inc
Deerfield Management Co
Vanguard Group Inc
Franklin Resources Inc
cullinan oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. sourced from the cullinan dry lab as well as external collaborators, cullinan’s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model.
Organization | Cullinan Therapeutics Inc |
Employees | 85 |
CEO | Mr. Nadim Ahmed |
Industry | Other Consumer Services |
Cactus Acquisition Corp 1 Ltd
$15.58
-5.46%
Rigel Resource Acquisition Corp
$15.58
-5.46%
Ft Energy Income Partners Strategy Etf
$15.58
-5.46%
Tian Ruixiang Holdings Ltd
$15.58
-5.46%
Invsc Bulletshares 2032 Corp
$15.58
-5.46%
Schwab International Dividend Equity Etf
$15.58
-5.46%
Fitell Corp
$15.58
-5.46%
Estrella Immunopharma Inc
$15.58
-5.46%
Abrdn Income Credit Strategies Fund
$15.58
-5.46%